Part 3: Opioid Risk Evaluation, Mitigation, and Management
December 15, 2022
December 15, 2023
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Postgraduate Institute for Medicine and Rural Medical Education (RME) Collaborative.
Supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS educational requirements issued by the US Food and Drug Administration.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
- Pharmacists — 1.0 Contact Hour
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is designed specifically for primary care clinicians, registered nurses, advanced practice registered nurses, pharmacists, and other members of the healthcare team.
The opioid epidemic is a national health crisis that results in tens of thousands of opioid-related overdose deaths annually. It is critical that the millions of patients with pain receive appropriate care while mitigating the risks of opioid misuse, abuse, and diversion. This CME/CE activity, which is Part 3 of a three-part series titled Tackling the Opioid Crisis: Strategies to Improve Best Practices and Patient Outcomes, will review fundamental elements of addiction and evidence-based strategies for recognizing and treating opioid use disorder. Best practices for counseling patients and caregivers about safe opioid use, storage, and disposal will also be discussed.
This activity meets most states’ requirements for opioid education and is fully compliant with the Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) education requirement issued by the FDA in September 2018.
Upon completion of this activity, participants should be better able to:
- Utilize appropriate methods for monitoring patients using opioid therapy
- Counsel patients about the safe use of opioids, safe disposal, potential for abuse and dependence, and overdose prevention (use of naloxone)
Michael J. Brennan, MD
Medical Director, Pain Center of Fairfield
Senior Attending Physician, Department of Medicine, Physical Medicine, and Rehabilitation
Jeffrey A. Gudin, MD
Professor of Anesthesiology, Perioperative Medicine, and Pain Management
University of Miami, Miller School of Medicine
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-374-H08-P)
Type of Activity: Application
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine and RME Collaborative adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Postgraduate Institute for Medicine requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies (commercial interests). All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to Postgraduate Institute for Medicine policy. Postgraduate Institute for Medicine is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Michael J. Brennan, MD, has disclosed the following relevant financial relationships: speaker fees from BioDelivery Sciences International, Inc., RedHill Biopharma Ltd., and SCILEX Pharmaceuticals, Inc.
Jeffrey A. Gudin, MD, has disclosed the following relevant financial relationships: consultant for Hisamitsu Pharmaceutical Co., Inc., Quest Diagnostics, and Sanofi; and grant/research support and ownership interest in Virpax Pharmaceuticals.
Planners, Managers, and Reviewer
The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.
Instructions for Participation and Credit
This activity is offered at no cost to participants. To receive CME/CE credit, participants must:
- Review the CME/CE information, including the learning objectives and disclosure statements.
- Complete the pre-test.
- View the online activity.
- Complete the post-test and evaluation form.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
©RME Collaborative, a division of Talem Health, LLC 2022. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.
There is no fee for this educational activity.
For general information or questions about this activity, please contact RME Collaborative at 800-913- 9370 or [email protected].
For questions regarding the certification of this activity, please contact Postgraduate Institute for Medicine at [email protected].